INDICATION AND LIMITATION OF USE

Vyvanse is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

This site is intended for US healthcare professionals only.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

  • CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Full Safety Information Below

Vyvanse is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

IMPORTANT SAFETY INFORMATION    This site is intended for US healthcare professionals only.

WARNING: ABUSE AND DEPENDENCE

  • | CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Full Safety Information Below

Shire has provided educational resources about ADHD to healthcare professionals and their patients for over a decade.

PRO RESOURCE CENTER
Take the guesswork out of your patients' co-pay with our formulary coverage tool

Check patient’s individual health plan coverage and costs as plan status may change without notice.

Formulary results* for

Health plan provider:

Status:

Co-pay:

Available health plan information:


Health plan:

*Results data are provided by Fingertip Formulary® as of .

Tier (Tier#) = A formulary category that determines the amount of co-pay required for a drug. The number of tiers varies by plan and can range from 1 to 7.

Prior authorization (PA) = Approval process in which a prescriber must justify the use of a prescribed medication.

Step edit (SE) = Prescription for a medication is filled only after treatment failure on one or more alternatives.

Not covered (NC) = Drugs that are not covered by the plan.

Not available (NA) = Data are not available.

Shire has provided educational resources about ADHD to healthcare professionals and their patients for over a decade.

HAVE A QUESTION? Request a representative to get answers

Thank you for your request.

A Vyvanse representative will be contacting you shortly.

    How would you like to be contacted?

    You are about to leave vyvansepro.com.

    Please be advised that Shire has no control over the content or presentation of the site you are about to view.

    Cancel Continue